Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will build upon a previous finding that showed a triglyceride lowering effect of
prescription omega-3 in combined therapy with statins. The proposed study will use a simple
change from baseline design on 15 subjects who are hypertriglyceridemic on stable statin
therapy. The protocol involves 3 study visits; each involve drawing a blood sample: day 1 -
screening (blood draw for qualification and safety); day 7 - before taking prescription
omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline), day 63 -after taking
prescription omega-3 fatty acids (Lovaza, 4 capsules/d; GlaxoSmithKline). The proposed study
will include up to 15 subjects and will utilize several different measures of lipoprotein
structure and function. The investigators will measure functional parameters such as the
binding affinity of lipoproteins before and after treatment with omega-3 fatty acids. The
investigators will also measure fatty acid, oxylipin and apolipoprotein content of plasma,
very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density
lipoprotein (HDL).